Clinical trial · Interventional
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epirubicin with a Taxane | Drug | — | UNRESOLVED |
| Epirubicin with Cyclophosphamide, followed by a Taxane | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- B
- description
- ET (8 cycles) T = docetaxel or paclitaxel
- interventionNames
- Drug: Epirubicin with a Taxane
- type
- EXPERIMENTAL
- label
- A
- description
- EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles T = docetaxel or paclitaxel
- interventionNames
- Drug: Epirubicin with Cyclophosphamide, followed by a Taxane
Primary outcomes (1)
- measure
- Disease free survival at 3 years
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast Cancer Stage T1-3, N1, M0 * Suitable candidate for anthracycline-containing adjuvant chemotherapy Exclusion Criteria: * Evidence of residual tumor following surgery, or metastatic disease * Received prior therapy for breast cancer
References
Publications (0)
Data not yet available